

Financial Results for the 2nd Quarter of FY2025 Supplement

October 27, 2025
SHIONOGI & CO., LTD.

1. Consolidated statement of profit or loss

(Billions of yen)

	FY2024 1H	FY2025 1H	Change	Change(%)	Comment	FY2025 forecast	Progress(%)
Revenue	214.0	213.0	(1.0)	(0.5)	Increasing/(decreasing) in Prescription drugs (10.9) billion Overseas subsidiaries/Export 2.3billion Royalty income 7.8billion	500.0	42.6
Cost of sales	(30.1)	(29.3)	(0.9)	(2.9)		(82.0)	35.7
Gross profit	183.8	183.7	(0.1)	(0.1)		418.0	43.9
SG&A expenses	(47.7)	(53.4)	5.6	11.8	Increase in sales-related expenses in the U.S. business and expenses associated with making Torii Pharmaceutical Co., Ltd. a wholly owned subsidiary	(116.2)	45.9
R&D expenses	(56.8)	(52.4)	(4.4)	(7.7)	Multiple large-scale clinical trials were conducted in FY2024	(120.0)	43.7
Amortization of intangible assets associated with products	(2.2)	(1.0)	(1.2)	(55.2)		(3.8)	25.5
Other income	0.5	0.5	(0.0)	(7.0)		7.0	-
Other expenses	(1.7)	(2.6)	0.9	51.2			
Operating profit	75.9	74.8	(1.1)	(1.4)		185.0	40.4
Finance income	23.6	27.8	4.2	17.8	Increase in dividends from ViiV	47.0	50.2
Finance costs	(5.6)	(4.2)	(1.5)	(25.9)			
Profit before tax	93.8	98.4	4.6	4.9		232.0	42.4
Income tax expense	(11.0)	(14.9)	3.9	35.5			
Profit	82.9	83.5	0.7	0.8			
Profit attributable to Owners of parent	83.1	83.5	0.4	0.5		188.0	44.4
Non-controlling interests	(0.3)	(0.0)	(0.3)	(95.8)			
Profit	82.9	83.5	0.7	0.8			

* SHIONOGI has revised its FY2025 forecast on October 27, 2025.

Reconciliation from operating profit to EBITDA

(Billions of yen)

	FY2024 1H	FY2025 1H
Operating profit	75.9	74.8
Other income	(0.2)	(0.0)
Other expenses	0.7	0.9
Core operating profit ^{*1}	76.4	75.7
Depreciation and amortization	10.3	10.2
EBITDA ^{*2}	86.7	85.8

*1. Core operating profit: An adjusted profit in which non-recurring items (impairment, gain on sales of property, plant, and equipment, etc.) are deducted from operating profit.

2. Earnings Before Interest, Taxes, Depreciation, and Amortization: Core operating profit added depreciation and amortization.

2. Revenue by segment

(Billions of yen)

	FY2024 1H	FY2025 1H	Change	Change(%)	FY2025 forecast	Progress(%)
Prescription drugs	47.7	36.8	(10.9)	(22.8)	143.5	25.7
Acute Respiratory Virus Infection Treatment	24.9	8.7	(16.2)	(65.1)	56.0	15.5
QUVIVIQ	-	0.4	0.4	-	2.5	17.1
SYMPROIC	2.4	2.9	0.6	23.9	6.5	45.3
OXYCONTIN Franchise	2.1	2.3	0.2	10.7	5.3	43.0
Others	18.4	22.5	4.1	22.1	73.2	30.7
Overseas subsidiaries/Export	28.3	30.6	2.3	8.1	61.0	50.2
Shionogi Inc. (US)	11.2	13.6	2.4	21.0	27.2	49.9
Shionogi B.V. (EU)	8.3	9.8	1.5	18.3	19.3	51.0
Shionogi China	4.2	3.0	(1.2)	(29.2)	5.9	50.0
Others	4.6	4.3	(0.4)	(7.6)	8.6	49.4
Contract manufacturing	7.8	7.1	(0.6)	(8.3)	14.0	50.8
OTC and quasi-drugs	8.2	7.9	(0.3)	(3.6)	17.5	44.9
Royalty income	121.5	129.3	7.8	6.4	261.5	49.4
HIV Franchise	119.6	125.8	6.2	5.2	245.0	51.3
Others	1.9	3.5	1.6	84.8	16.5	21.3
Others	0.5	1.2	0.7	135.4	2.5	48.8
Total	214.0	213.0	(1.0)	(0.5)	500.0	42.6

*1. Sales of prescription drugs are shown on non-consolidated basis.

2. Products included in Acute Respiratory Virus Infection Treatment: COVID-19 Treatment "Xocova", Influenza Franchise "Xofluza" and "Rapiacta"

3. SHIONOGI has revised its FY2025 forecast on October 27, 2025.

3. Quarterly trend (Consolidated statement of profit or loss)

(Billions of yen)

	FY2024				FY2025							
	1Q	2Q	3Q	4Q	1Q	Y on Y change (%)	2Q	Y on Y change (%)	3Q	Y on Y change (%)	4Q	Y on Y change (%)
Revenue	97.6	116.4	119.6	104.7	99.8	2.2	113.2	(2.7)				
Cost of sales	(14.4)	(15.7)	(15.9)	(17.8)	(12.3)	(14.7)	(16.9)	7.9				
Gross profit	83.1	100.7	103.7	86.9	87.5	5.2	96.2	(4.4)				
SG&A expenses	(24.0)	(23.7)	(25.5)	(28.7)	(25.8)	7.4	(27.6)	16.3				
R&D expenses	(29.4)	(27.4)	(22.6)	(29.2)	(24.9)	(15.4)	(27.5)	0.6				
Amortization of intangible assets associated with products	(1.1)	(1.1)	(1.1)	(0.9)	(0.5)	(55.7)	(0.5)	(54.7)				
Other income	0.1	0.4	0.0	0.0	0.1	11.3	0.4	(10.4)				
Other expenses	(0.5)	(1.2)	(1.2)	(0.8)	(1.3)	132.6	(1.3)	13.9				
Operating profit	28.1	47.8	53.4	27.4	35.1	24.9	39.7	(16.9)				
Finance income	11.3	13.9	10.2	21.0	13.6	20.5	14.2	2.1				
Finance costs	(2.8)	(4.4)	(1.5)	(3.5)	(2.3)	(17.9)	(1.8)	(58.2)				
Profit before tax	36.5	57.3	62.0	44.9	46.3	26.8	52.1	(9.2)				
Income tax expense	(6.2)	(4.7)	(11.6)	(8.7)	(7.0)	12.3	(7.9)	66.0				
Profit	30.3	52.6	50.5	36.2	39.3	29.8	44.2	(15.9)				
Profit attributable to Owners of parent	30.6	52.5	50.7	36.6	39.4	28.5	44.2	(15.8)				
Non-controlling interests	(0.3)	0.1	(0.2)	(0.4)	(0.0)	(97.7)	0.0	(104.6)				
Profit	30.3	52.6	50.5	36.2	39.3	29.8	44.2	(15.9)				

4. Quarterly trend (Revenue by segment)

(Billions of yen)

	FY2024				FY2025							
	1Q	2Q	3Q	4Q	1Q	Y on Y change (%)	2Q	Y on Y change (%)	3Q	Y on Y change (%)	4Q	Y on Y change (%)
Prescription drugs	15.4	32.3	31.2	19.8	14.1	(8.5)	22.7	(29.7)				
Acute Respiratory Virus Infection Treatment	3.9	21.0	18.5	8.5	2.9	(25.8)	5.8	(72.4)				
QUVIVIQ	-	-	0.5	0.3	0.1	-	0.3	-				
SYMPROIC	1.1	1.3	1.5	1.2	1.5	35.3	1.5	14.2				
OXYCONTIN Franchise	1.0	1.0	1.2	0.9	1.1	8.3	1.2	13.1				
Others	9.4	9.0	9.6	8.9	8.5	(9.4)	14.0	55.0				
Overseas subsidiaries/Export	15.0	13.4	15.0	15.7	14.2	(4.9)	16.4	22.7				
Shionogi Inc. (US)	6.0	5.2	6.3	5.9	6.2	3.7	7.4	40.9				
Shionogi B.V. (EU)	4.0	4.3	4.6	3.9	4.7	17.4	5.1	19.2				
Shionogi China	2.3	1.9	2.1	2.4	1.5	(34.7)	1.5	(22.5)				
Others	2.7	1.9	2.1	3.5	1.8	(31.6)	2.4	25.9				
Contract manufacturing	3.6	4.2	2.9	6.6	4.5	24.1	2.7	(36.2)				
OTC and quasi-drugs	2.4	5.7	4.5	4.1	2.4	0.1	5.4	(5.1)				
Royalty income	61.0	60.5	65.3	57.9	63.9	4.7	65.4	8.1				
HIV Franchise	59.8	59.8	63.9	56.9	61.2	2.3	64.6	8.1				
Others	1.2	0.7	1.4	1.0	2.7	125.0	0.8	13.0				
Others	0.2	0.4	0.6	0.6	0.6	282.1	0.6	66.5				
Total	97.6	116.4	119.6	104.7	99.8	2.2	113.2	(2.7)				

*1. Sales of prescription drugs are shown on non-consolidated basis.

2. Products included in Acute Respiratory Virus Infection Treatment: COVID-19 Treatment "Xocova", Influenza Franchise "Xofluza" and "Rapiacta"

5. Consolidated statement of financial position

(Billions of yen)

	As of Mar. 31 2025	As of Sep. 30 2025	Y on Y change	Comment
Assets				
Non-current assets				
Property, plant and equipment	115.4	118.5	3.1	
Goodwill	15.7	39.3	23.6	Increase due to the consolidation of Torii Pharmaceutical Co., Ltd. as a subsidiary
Intangible assets	143.7	154.8	11.2	Increase due to the consolidation of Torii Pharmaceutical Co., Ltd. as a subsidiary
Right-of-use assets	19.4	19.7	0.3	
Investment property	27.7	27.8	0.1	
Other financial assets	299.8	348.3	48.5	Increase due to the consolidation of Torii Pharmaceutical Co., Ltd. as a subsidiary
Deferred tax assets	13.2	8.8	(4.4)	
Other non-current assets	41.9	49.6	7.7	
Total non-current assets	676.8	766.9	90.0	
Current assets				
Inventories	65.5	92.7	27.2	Increase due to the consolidation of Torii Pharmaceutical Co., Ltd. as a subsidiary
Trade receivables	120.6	147.0	26.4	Increase due to the consolidation of Torii Pharmaceutical Co., Ltd. as a subsidiary
Other financial assets	270.0	350.1	80.1	Increase in time deposits over 3 months and bonds
Other current assets	27.7	26.2	(1.4)	
Cash and cash equivalents	374.8	233.9	(140.9)	Decrease due to acquisition of Torii Pharmaceutical Co., Ltd. shares, time deposits over 3 months and bonds
Total current assets	858.5	849.8	(8.7)	
Total assets	1,535.3	1,616.7	81.4	

* The amounts of goodwill, etc. that increased following Torii Pharmaceutical Co., Ltd. becoming a consolidated subsidiary are the provisionally calculated amounts as the allocation of the acquisition cost has not yet been completed.

Equity and liabilities				
Equity				
Share capital	21.3	21.3	—	
Capital surplus	17.8	17.8	(0.0)	
Treasury shares	(65.9)	(65.2)	(0.7)	
Retained earnings	1,115.7	1,167.5	51.8	
Other components of equity	272.9	291.5	18.6	Increase in the valuation of listed stocks, and exchange differences on translation of foreign operations
Equity attributable to owners of parent	1,361.9	1,432.9	71.0	
Non-controlling interests	0.6	7.5	6.9	
Total equity	1,362.5	1,440.4	77.9	
Liabilities				
Non-current liabilities				
Lease liabilities	18.4	18.2	(0.3)	
Other financial liabilities	8.3	7.9	(0.4)	
Retirement benefit liability	8.0	8.3	0.3	
Deferred tax liabilities	4.4	4.4	(0.0)	
Other non-current liabilities	4.4	5.7	1.4	
Total non-current liabilities	43.5	44.5	1.0	
Current liabilities				
Lease liabilities	3.5	4.5	1.1	
Trade payables	13.6	22.2	8.6	
Other financial liabilities	18.1	21.7	3.6	
Income taxes payable	22.4	18.1	(4.3)	
Other current liabilities	71.9	65.3	(6.5)	
Total current liabilities	129.4	131.9	2.5	
Total liabilities	172.9	176.3	3.5	
Total equity and liabilities	1,535.3	1,616.7	81.4	

6. Management index

		FY2024				FY2025			
		Apr.-Jun.	Apr.-Sep.	Apr.-Dec.	Apr.-Mar.	Apr.-Jun.	Apr.-Sep.	Apr.-Dec.	Apr.-Mar.
STS2030 Revision Growth									
Revenue	Billions of yen	97.6	214.0	333.6	438.3	99.8	213.0		
Overseas sales CAGR *1	%	-	-	-	17.9	-	-		
EBITDA	Billions of yen	33.1	86.7	146.4	179.3	40.6	85.8		
STS2030 Revision Shareholder return									
Basic earnings per share *2	yen	36.02	97.74	157.30	200.36	46.26	98.19		
Diluted earnings per share *2	yen	36.01	97.70	157.25	200.29	46.25	98.16		
Ratio of dividends to equity attributable to owners of parent (DOE)	%	-	-	-	4.0	-	-		
Return on equity attributable to owners of parent (ROE)	%	2.4	6.6	10.4	13.1	2.9	6.0		
Others									
Ratio of profit before tax to total assets (ROA)	%	2.5	6.5	10.6	13.6	3.0	6.2		
Ratio of operating profit to revenue	%	28.8	35.5	38.7	35.7	35.2	35.1		
Ratio of equity attributable to owners of parent to total assets	%	87.9	88.7	88.7	88.7	89.6	88.6		
Dividend payout ratio	%	-	-	-	30.6	-	-		

*1. Excluding royalty income, starting from FY2022

*2. The Company conducted a 3-for-1 stock split of shares of common stock, effective October 1, 2024. Basic earnings per share and Diluted earnings per share were calculated under the assumption that the stock split had been conducted at the beginning of FY2024.

7. Employees

		FY2024				FY2025			
		As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31
Employees	Persons	5,001	4,990	4,944	4,955	5,039	5,613		

* The increase in FY2025 is primarily due to Torii Pharmaceutical Co., Ltd. becoming a consolidated subsidiary in September 2025.

8. Capital investments and Depreciation and Amortization

(Billions of yen)

	FY2024 Apr.-Sep.	FY2025 Apr.-Sep.	Change	Change(%)	FY2025 forecast	Progress(%)
Investments in equipments	3.0	6.9	3.9	127.0	23.3	29.6
Depreciation and Amortization	10.3	10.2	(0.1)	(1.2)	20.3	50.1
Property, plant and equipment	5.7	6.0	0.3	4.6		
Intangible assets	3.1	2.0	(1.1)	(35.2)		
Right-of-use assets	1.3	1.9	0.7	50.4		
Investment property	0.1	0.2	0.1	49.4		

* SHIONOGI has revised its FY2025 forecast on October 27, 2025.

9. Exchange rate

	FY2024 Apr.-Sep.		FY2024		FY2025 Apr.-Sep.		FY2025 forecast
	CR	AR	CR	AR	CR	AR	AR
USD	142.82	152.78	149.53	152.62	148.81	146.03	146
GBP	191.15	195.57	193.76	194.73	199.72	195.96	197
EUR	159.53	166.06	162.05	163.88	174.39	168.06	171

* SHIONOGI has revised its FY2025 forecast on October 27, 2025.

10. Pipeline (as of October 27, 2025)

Areas	Generic name/Code No. [Product name]	Mechanism of action (Administration)	Indication	Stage	Origin	Development
Infectious disease	Cefiderocol Tosilate Sulfate Hydrate [US, Japan: Fetroja®] [EU:Fetroja®]	Cell-wall synthesis inhibition (injection)	Gram-negative infection (pediatric)	Phase III	In-house	In-house
			Gram-negative infection	Phase III NDA submission: China (Aug. 2024) MAA submission: Australia (Dec. 2024)	In-house	In-house
	Baloxavir marboxil [USA:Xofluza™] [Japan:Xofluza®]	Cap-dependent endonuclease inhibition (oral, granule)	Influenza virus infection (body weight <20kg)	Approval: Japan (Sep. 2025)	In-house	In-house/ Roche (Switzerland)
	S-268019 [Japan:Covgoze®]	Vaccine (muscular injection)	Prevention of COVID-19 (Adolescent)	Phase II/III	In-house	In-house
			Prevention of COVID-19 (Children)	Phase I/II/III	In-house	In-house
	S-268023	Vaccine (muscular injection)	Prevention of COVID-19	Phase III	In-house	In-house
	S-268024	Vaccine (muscular injection)	Prevention of COVID-19	Phase III	In-house	In-house
	Ensitrelvir Fumaric Acid [Japan:Xocova®]	3CL protease inhibitor (oral)	Treatment of COVID-19 (12 years old and older)	Phase III NDA submission: Taiwan (Jan. 2025) EU (Jun. 2025)	In-house	Japan, global, Taiwan: In-house South Korea: In-house /Ildong Singapore:In-house /Juniper
			Treatment of COVID-19 (Children, 6 to 11 years)	NDA submission: Japan (Jun. 2025)	In-house	In-house
			Post exposure prophylaxis of COVID-19	NDA submission: Japan (Mar. 2025) US (Jun. 2025) EU (Jun. 2025)	In-house	In-house
	Olorofim	Dihydroorotate dehydrogenase (DHODH) inhibition (oral)	Invasive aspergillosis	Phase III	F2G (UK)	In-house/ F2G
	S-892216	3CL protease inhibitor (oral)	Treatment of COVID-19	Phase II	In-house	In-house
		3CL protease inhibitor (long-acting injection)	Pre exposure prophylaxis of COVID-19	Phase I	In-house	In-house
	S-337395	RNA dependent RNA polymerase inhibitor (oral)	Treatment of RSV infection	Phase II	In-house/ UBE	In-house/ UBE
	S-743229	Cell-wall synthesis inhibition (oral)	Complicated urinary tract infections, including pyelonephritis	Phase I	In-house/ Qpex	In-house
	S-649228	Cell-wall synthesis inhibition (injection)	Gram-negative infection	Phase I	In-house/ Qpex	In-house
QOL Diseases	Naldemedine tosilate [Japan:Symproic®] [EU:Rizmoic®]	Peripheral opioid receptor antagonist (oral, powder)	Opioid-induced constipation (pediatric)	Phase I/II	In-house	In-house
		Peripheral opioid receptor antagonist (oral)	Opioid-induced constipation	Phase III NDA submission: China (May. 2025)	In-house	In-house
	Zuranolone	GABA _A receptor positive allosteric modulator (oral)	Depression	NDA submission: Japan (Sep. 2024)	Supernus (USA)	In-house/ Supernus
	SDT-001 [Japan:ENDEAVORRIDE®]	Treatment digital application based on cerebral mechanism	Treatment of ADHD (pediatric)	Approval: Japan (Feb. 2025)	Akili (USA)	In-house/ Akili
	Zatolmilast	PDE4D negative allosteric modulator (oral)	Fragile X syndrome	Phase II/III	Tetra (USA)	In-house
			Jordan syndrome	Phase II	Tetra (USA)	In-house
			Alzheimer's disease	Phase II	Tetra (USA)	In-house
	Resiniferatoxin	TRPV1 agonist (Intra-articular injection)	Pain associated with osteoarthritis of knee	Phase III	Grünenthal (Germany)	Grünenthal
	S-151128	Nav1.7 inhibitor (injection)	Chronic pain	Phase I	In-house	In-house
	ADR-001	Human mesenchymal stem cells (injection)	Decompensated liver cirrhosis	Phase I/II	Rohto (Japan)	In-house/ Rohto
	S-309309	Monoacylglycerol acyltransferase 2 inhibitor (oral)	Obesity	Phase II	In-house	In-house
	S-588410	Cancer peptide vaccine (injection)	Esophageal cancer	Phase III	OncoTherapy Science, Inc.(Japan)	In-house
			Bladder cancer	Phase II	OncoTherapy Science, Inc.(Japan)	In-house
	S-488210	Cancer peptide vaccine (injection)	Head and neck squamous cell carcinoma	Phase I/II	OncoTherapy Science, Inc.(Japan)	In-house

Areas	Generic name/Code No. [Product name]	Mechanism of action (Administration)	Indication	Stage	Origin	Development
QOL Diseases	S-588210	Cancer peptide vaccine (injection)	Solid tumor	Phase I	OncoTherapy Science, Inc. (Japan)	In-house
	S-222611 (Epertinib)	HER2/EGFR dual inhibitor (oral)	Malignant tumor	Phase I/II	In-house	In-house
	SR-0379	Promote granulation formation (topical)	Cutaneous ulcer (Pressure ulcer, Diabetic ulcer)	Phase III	FunPep (Japan)	In-house/ FunPep
	Redasemide Trifluoroacetate	Mobilization of mesenchymal stem cells (MSCs) to peripheral blood (injection)	Stroke	Phase IIb	StemRIM (Japan)	In-house
			Epidermolysis bullosa	Phase II	StemRIM (Japan)	In-house
	S-531011	anti-CCR8 antibody (injection)	Solid tumor	Phase Ib/II	In-house	In-house
	S-740792	New mechanism of action (oral)	Walking impairment associated with multiple sclerosis	Phase I	In-house	In-house
	SASS-001 (S-600918 + Concomitant drug X)	P2X3 receptor inhibitor (oral) + Mechanism of Concomitant drug	Sleep Apnea with a Central Component	Phase II	S-600918: In-house	Shionogi-Aprimed Sleep Science, LLC (USA)
	S-606001	Glycogen synthase 1 (GYS1) inhibitor (oral)	Pompe disease	Phase II	Maze (USA)	In-house
	SDS-881	AI Programmed Medical Device for Conversational Cognitive Function Testing	Cognitive impairment in dementia	Phase III	FRONTEO (Japan)	In-house
	S-898270	Phosphodiesterase 4D (PDE4D) Inhibitors	Alzheimer's Disease	Phase I	In-house	In-house
	SASS-002 (Sulthiame)	Carbonic anhydrase inhibitor	Obstructive Sleep Apnea	Phase II	Desitin	Shionogi-Aprimed Sleep Science, LLC (USA)
	Tapinarof	Aryl hydrocarbon receptor (AhR) modulating agent (Topical)	Atopic dermatitis in Pediatric Patients	NDA submission: Japan (Oct. 2025)	Dermavant (Switzerland)	In-house/JT (Japan)
			Atopic dermatitis in Infants Patients	Phase III	Dermavant (Switzerland)	In-house/JT (Japan)
	Cantharidin [YCANTH®topical solution0.71%]	Treatment for viral warts (Topical)	Molluscum Contagiosum	Approval: Japan (Sep. 2025)	Verrica (USA)	In-house
	Cantharidin		Common Warts	Phase II*	Verrica (USA)	In-house (Japan) /Verrica (USA)
	TO-210	Peroxisome proliferator-activated receptor γ (PPAR γ) modulating agent (Topical)	Acne vulgaris	Phase III	Nogra (Ireland)	In-house
	TO-203 [MITICURE®House Dust Mite Sublingual Tablets]	Allergen Immunotherapy (Sublingual tablet)	House dust mite inducedallergic asthma	Phase II/III	ALK (Denmark)	In-house
	TO-209	Allergen Immunotherapy (Sublingual tablet)	Grass pollen-induced allergic rhinitis	Phase III	ALK (Denmark)	In-house

* Conducted by Verrica in the US

<Out-Licensing Activity>

Generic name/Code No. [Product name]	Mechanism of action (Administration)	Indication	Stage	Origin	Development
Baloxavir marboxil [USA:Xofluza™] [Japan:Xofluza®]	Cap-dependent endonuclease inhibition (oral)	Influenza virus infection (pediatric, < 1 year old)	Approval: EU (May.2025)	In-house	In-house/ Roche (Switzerland)
		Influenza virus infection (transmission)	NDA submission: USA (Nov. 2024)	In-house	In-house/ Roche (Switzerland)
S-723595 (TLC-3595)	Acetyl-CoA carboxylase 2 inhibitor (oral)	Type 2 diabetes	Phase IIa	In-house	OrsoBio, Inc. (USA)
S-365598	Integrase inhibitor (ultra long-acting injection)	HIV infection	Phase IIa	In-house	SHIONOGI-ViiV Healthcare LLC

Since July 28, 2025

Change	Baloxavir marboxil (Influenza virus infection, body weight <20kg) : Japan:NDA submission→ Apprpval
Add	Tapinarof (Atopic dermatitis in Pediatric Patients) : NDA submission
	Tapinarof (Atopic dermatitis in infants) : Phase III
	Cantharidin (Molluscum Contagiosum) : Approval
	Cantharidin (Common Warts) : Phase II
	TO-210: PhaseIII
	TO-203: Phase II/III
	TO-209: Phase III